Publication of our review on the viral-like particles bioprocesses.
This review aims to give an overview of available strategies for influenza VLP production and their respective stage of development, from small-scale preclinical studies to large-scale industrial processes. Recent trends and fulfillments in purification schemes of influenza VLP were also reviewed with regards to quality and potency requirements that go along with influenza vaccine manufacturing.
Signia Therapeutics, Cynbiose and our laboratory VirPath announce the launch of the METABIOSE project, winner of the 2019 R&D Booster award, supported by the Regional Innovation Fund of the Auvergne Rhône Alpes region.
The METABIOSE project aims to develop and characterize a translational model of metapneumovirus infection (hMPV), then to validate in preclinical studies a drug repositioned as a pneumovirus inhibitor from Signia Therapeutics's portfolio, as well as a new nebulization delivery thanks to an approved medical device. On the medical and social level, this project will contribute significantly to the development of a future treatment for the bronchiolitis and pneumovirus pneumopathy that is lacking today.
Here you can find the english and french press releases :
Our spin offs Signia Therapeutics and Vaxxel were highlighted in the Pulsalys success book 2019.
Dr Mario Andrès Pizzorno was invited to present Signia Therapeutics and drug repurposing technologies at the third edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2019), in Lyon, France on December 4-5, 2019.
Our results show for the first time that the viral genetic backbone should be considered in the design of live-attenuated HMPV vaccine candidates, and that a SH-deleted virus based on our proprietary A1/C-85473 HMPV strain could be a promising LAV candidate as it is both attenuated and protective in mice while being efficiently produced in a cell-based system.
Publication of our study on the use of the calixarene-based surfactant CALX133ACE as an alternative to classical detergents for influenza inactivated split vaccine preparation.
Our results demonstrate for the first time the use of a calixarene-based detergent as an efficient splitting agent for the production of optimized influenza split antigens, paving the way for significant improvement in the vaccine manufacturing process, notably with regard to the current regulation on the prohibition of endocrine disruptors, such as Triton X-100.
VirPath patent granted in Europe: Innovative splitting method for the preparation of vaccine influenza antigens. EP3194423 (B1)
After the United States Patent Office in last June, VirPath announces the grant of its patent for the preparation of influenza antigens using an innovative splitting approach for the formulation of novel vaccines by the European Patent Office. This patent is issued from a fruitful collaboration with the company Calixar that took the operating license and our Technology Research Platform VirNext.
Vaxxel has been highlighted on the french website of "Les Echos".
Our results show that the viral genetic backbone should be considered in the design of live-attenuated HMPV vaccines, and that a SH-deleted virus based on the A1/C-85473 HMPV strain could be a promising LAV candidate as it is both attenuated and protective in mice, yet not inducing enhanced disease markers, while being efficiently produced in a cell-based system.
Vaxxel has been highlighted on the website of the University Claude Bernard Lyon 1.
Récompensée lors du concours i-Lab 2019 pour son engagement dans la lutte contre les infections respiratoires à pneumovirus, la startup VAXXEL, soutenue par PULSALYS et issue du Laboratoire de virologie VirPath rattaché au Centre International de Recherche en Infectiologie (CIRI : INSERM, CNRS, UCBL, HCL, ENS), vise la mise au point d’un nouveau vaccin pédiatrique intranasal. Alors qu’aucun vaccin n’est disponible sur le marché contre ces pathologies, ce futur candidat vaccin bivalent ciblera à la fois les pneumovirus hMPV (métapneumovirus humain, découvert récemment) et hRSV (virus respiratoire syncitial, VRS), tous deux en cause dans les bronchiolites et pneumonies, notamment chez les nourrissons.
Very pleased to announce that Dr. Andrés Pizzorno has been invited by the Scientific Committee of the Options for the Control of Influenza X Conference, to be held in Singapore from August 28 to September 1 2019, to give a presentation on “Potential host-targeted therapies for influenza”. The presentation - on Friday August 30 at 10.30 am - will showcase an update of the current clinical trial landscape in the field and a discussion on the future research directions in order to consolidate the host-targeted anti-influenza agents as an important contribution to our limited therapeutic arsenal, not only as putative standalone therapies but also with special focus on their combinatory potential with current classic virus-targeted inhibitors.
The Options X Conference is the premier global meeting focused on influenza, targeting more than 1,500 participants from across the globe. Visit the ISIRV Options X website (https://2019.isirv.org/) for detailed information.
Publication of our latest comparative study of virogenomic signatures of different major respiratory viruses (Influenza viruses, hRSV and hMPV) in a physiological model of reconstituted human airway epithelium.
This set of data constitutes a very promising starting point for the future characterization of new biomarkers of diagnostic interest, or as surrogates for the efficacy evaluation of innovative broad-spectrum host-targeted antimicrobial therapeutic strategy.
The French National Research Agency (ANR) has selected and will fund our METAVAC-T17 project.
Based on the molecular engineering of pneumoviruses, this project aims to develop innovative vaccines. The METAVAC-T17 project will be carried out by our team Virpath (CIRI U1111 INSERM - UMR 5308 CNRS - ENS Lyon - UCBL1) and its Technology Research platform VirNext in close collaboration with our partners, the Molecular Biology of Pneumoviruses team (UVIM UR0892 INRA) and the Research Laboratory LAGEPP (UMR 5007 CNRS-UCBL1).
Signia Therapeutics has been highlighted in the 2018 annual report of the CNRS.
This report presents a selection of scientific results and highlights the strategy of CNRS in terms of partnerships and upgrading.
The Technology Transfer Accelerator Office PULSALYS supports the development of our spin-off Vaxxel.
Denis CAVERT, CEO of Vaxxel, has been interviewed by Nathaly Mermet. Complete interview is available on the website of PULSALYS.
Very proud to announce that our second spin-off Vaxxel is laureate of the iLab 2019 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance.
The iLab2019 trophy has been awarded to Vaxxel and its co-founders (Denis CAVERT, Manuel ROSA-CALATRAVA and Julia DUBOIS) in presence of the French Ministry Frédérique VIDAL.